Axonics, Inc.
Clinical trials sponsored by Axonics, Inc., explained in plain language.
Now part of
Boston Scientific Corporation
BSX
NYSE
Medical device company focused on sacral neuromodulation for bladder and bowel disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New device trial offers hope for bladder and bowel leakage Results expected Nov 2026 (estimated)
- No more charging: new implant aims to ease bladder and bowel leaks Results expected Dec 2026 (estimated)
- Rechargeable implant offers hope for bladder control – but does it last? Results expected Jan 2027 (estimated)
- New implant aims to control bowel leakage Results expected Aug 2027 (estimated)